Imipramine and Flecainide Interaction

Understanding the Imipramine and Flecainide Interaction

FDA-approved prescribing information for these two drugs flags their combination as a minor-severity interaction. Imipramine belongs to the Tricyclic Antidepressant (TCA) class and Flecainide belongs to the Class IC Antiarrhythmic class - two categories that can collide when co-prescribed. The mechanism described in FDA labeling is: Both drugs are processed by the same liver enzyme, which can cause them to compete and build up in your system. Severity tiers matter: major flags generally advise avoidance, moderate flags often require monitoring or dose adjustment, and minor flags may only call for awareness.

Context around a specific patient determines real-world impact. Imipramine has 20 total documented interactions on file in this dataset, and Flecainide has 22. Each additional medication compounds the interaction surface, which is why pharmacists run full-profile checks rather than evaluating one pair at a time. FDA-derived guidance for this pair is: Your doctor may need to monitor you closely for side effects or adjust your medication doses. Timing of doses, renal and hepatic function, age, and other concurrent prescriptions all shape whether a labeled interaction matters clinically.

An interaction flag is not a verdict. A large share of labeled interactions are managed routinely in clinical practice, the fix may be as simple as spacing doses or adding a monitoring test. Others require the prescriber to choose a different medication entirely. This page surfaces FDA-sourced labeling and openFDA data for educational purposes only; it is not medical advice and cannot account for your full clinical picture. Never start, stop, or adjust either Imipramine or Flecainide based on a web page, speak with your prescriber or pharmacist before making any change.